A detailed history of Alliancebernstein L.P. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 85,310 shares of BEAM stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,310
Previous 88,110 3.18%
Holding current value
$2.05 Million
Previous $2.06 Million 1.26%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$22.57 - $33.14 $63,196 - $92,792
-2,800 Reduced 3.18%
85,310 $2.09 Million
Q1 2024

May 14, 2024

BUY
$23.46 - $45.07 $91,024 - $174,871
3,880 Added 4.61%
88,110 $2.91 Million
Q4 2023

Feb 14, 2024

BUY
$17.69 - $30.76 $37,149 - $64,596
2,100 Added 2.56%
84,230 $2.29 Million
Q3 2023

Nov 14, 2023

SELL
$23.01 - $32.46 $170,274 - $240,204
-7,400 Reduced 8.27%
82,130 $1.98 Million
Q2 2023

Aug 15, 2023

BUY
$29.32 - $35.99 $569,687 - $699,285
19,430 Added 27.72%
89,530 $2.86 Million
Q3 2022

Nov 15, 2022

BUY
$39.79 - $70.31 $11,937 - $21,093
300 Added 0.43%
70,100 $3.34 Million
Q2 2022

Aug 15, 2022

BUY
$29.86 - $62.36 $394,152 - $823,152
13,200 Added 23.32%
69,800 $2.7 Million
Q1 2022

May 13, 2022

BUY
$53.73 - $82.16 $10,746 - $16,432
200 Added 0.35%
56,600 $3.24 Million
Q3 2021

Nov 10, 2021

BUY
$84.37 - $133.6 $168,740 - $267,200
2,000 Added 3.68%
56,400 $4.91 Million
Q2 2021

Jul 30, 2021

BUY
$64.12 - $128.71 $275,716 - $553,453
4,300 Added 8.58%
54,400 $7 Million
Q4 2020

Feb 08, 2021

BUY
$22.24 - $95.63 $80,064 - $344,268
3,600 Added 7.74%
50,100 $4.09 Million
Q3 2020

Nov 12, 2020

BUY
$19.0 - $30.57 $338,200 - $544,146
17,800 Added 62.02%
46,500 $1.15 Million
Q2 2020

Aug 13, 2020

BUY
$15.26 - $28.66 $268,576 - $504,416
17,600 Added 158.56%
28,700 $804,000
Q1 2020

May 14, 2020

BUY
$13.31 - $29.2 $147,741 - $324,120
11,100 New
11,100 $200,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.69B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.